Susan E. Morgan-Lappe

1.4k total citations
20 papers, 1.1k citations indexed

About

Susan E. Morgan-Lappe is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Susan E. Morgan-Lappe has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Immunology. Recurrent topics in Susan E. Morgan-Lappe's work include Cell death mechanisms and regulation (9 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer Research and Treatments (3 papers). Susan E. Morgan-Lappe is often cited by papers focused on Cell death mechanisms and regulation (9 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer Research and Treatments (3 papers). Susan E. Morgan-Lappe collaborates with scholars based in United States, United Kingdom and Japan. Susan E. Morgan-Lappe's co-authors include Stephen W. Fesik, Lawrence A. Vernetti, Dorothy Zakula, Aparna V. Sarthy, Mark G. Anderson, Mark E. Schurdak, Yu Shen, Xiaoyu Lin, Stephen K. Tahir and Jun Chen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Susan E. Morgan-Lappe

20 papers receiving 1.1k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Susan E. Morgan-Lappe 827 406 190 171 83 20 1.1k
Ángel Santiago 697 0.8× 325 0.8× 261 1.4× 137 0.8× 46 0.6× 16 908
Steven A. Enkemann 783 0.9× 414 1.0× 246 1.3× 185 1.1× 100 1.2× 31 1.3k
Linda Kessler 746 0.9× 352 0.9× 75 0.4× 127 0.7× 59 0.7× 38 1.1k
David Batt 944 1.1× 411 1.0× 166 0.9× 111 0.6× 96 1.2× 21 1.3k
Gaynor Davies 576 0.7× 351 0.9× 255 1.3× 87 0.5× 107 1.3× 22 1.0k
Maria F. Camargo 586 0.7× 365 0.9× 212 1.1× 175 1.0× 139 1.7× 18 966
Hui Qu 908 1.1× 412 1.0× 162 0.9× 300 1.8× 37 0.4× 36 1.3k
Alejandro Parrales 698 0.8× 463 1.1× 348 1.8× 173 1.0× 66 0.8× 19 1.1k
Akriti Kharbanda 705 0.9× 349 0.9× 218 1.1× 141 0.8× 106 1.3× 14 928
Lena Kanter 959 1.2× 628 1.5× 301 1.6× 179 1.0× 99 1.2× 39 1.3k

Countries citing papers authored by Susan E. Morgan-Lappe

Since Specialization
Citations

This map shows the geographic impact of Susan E. Morgan-Lappe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan E. Morgan-Lappe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan E. Morgan-Lappe more than expected).

Fields of papers citing papers by Susan E. Morgan-Lappe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan E. Morgan-Lappe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan E. Morgan-Lappe. The network helps show where Susan E. Morgan-Lappe may publish in the future.

Co-authorship network of co-authors of Susan E. Morgan-Lappe

This figure shows the co-authorship network connecting the top 25 collaborators of Susan E. Morgan-Lappe. A scholar is included among the top collaborators of Susan E. Morgan-Lappe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan E. Morgan-Lappe. Susan E. Morgan-Lappe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tahir, Stephen K., Emiliano Calvo, Benedito A. Carneiro, et al.. (2023). Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 141(17). 2114–2126. 9 indexed citations
2.
LoRusso, Patricia, Mark J. Ratain, Toshihiko Doi, et al.. (2022). Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Investigational New Drugs. 40(4). 762–772. 19 indexed citations
3.
Phillips, Darren C., Fritz G. Buchanan, Dong Cheng, et al.. (2021). Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors. Cancer Research. 81(12). 3402–3414. 32 indexed citations
4.
Gordon, Michael S., John Nemunaitis, Minal Barve, et al.. (2021). Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 20(10). 1988–1995. 10 indexed citations
5.
Smith, Morey L., Sha Jin, Chen Dong, et al.. (2020). The Combinatorial Activity of Eftozanermin (ABBV-621), a Novel and Potent TRAIL Receptor Agonist Fusion Protein, in Pre-Clinical Models of Hematologic Malignancies. Blood. 136(Supplement 1). 41–41. 3 indexed citations
6.
Purcell, James W., Jonathan A. Hickson, Melvin Fox, et al.. (2018). LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates. Cancer Research. 78(14). 4059–4072. 136 indexed citations
7.
Li, Yingchun, Jonathan A. Hickson, Deanna L. Haasch, et al.. (2018). ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models. Molecular Cancer Therapeutics. 17(5). 1039–1050. 35 indexed citations
8.
Ben‐Ami, Eytan, Ying Huang, Prafulla C. Gokhale, et al.. (2018). Abstract 953: LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085. Cancer Research. 78(13_Supplement). 953–953. 4 indexed citations
9.
Singh, Shweta, Claus Krebber, Shouchun Liu, et al.. (2018). Abstract B103: A multi-analyte HPLC-MS/MS approach to assessing exposure of a Probody drug conjugate in preclinical studies. Molecular Cancer Therapeutics. 17(1_Supplement). B103–B103. 3 indexed citations
10.
Tahir, Stephen K., Morey L. Smith, Larry R. Solomon, et al.. (2017). Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors. Blood. 130. 2812–2812. 8 indexed citations
11.
12.
Gordon, Michael S., John Nemunaitis, Ramesh K. Ramanathan, et al.. (2016). Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 2507–2507. 4 indexed citations
13.
Hickson, Jonathan A., Melvin Fox, David Chao, et al.. (2016). ABBV-085 is a novel antibody–drug conjugate (ADC) that targets LRRC15 in the tumor microenvironment. European Journal of Cancer. 69. S10–S10. 1 indexed citations
14.
Lu, Yiling, Mathias Müller, David M. Smith, et al.. (2011). Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene. 30(45). 4567–4577. 57 indexed citations
15.
Zheng, Min, Susan E. Morgan-Lappe, Jie Yang, et al.. (2008). Growth Inhibition and Radiosensitization of Glioblastoma and Lung Cancer Cells by Small Interfering RNA Silencing of Tumor Necrosis Factor Receptor–Associated Factor 2. Cancer Research. 68(18). 7570–7578. 87 indexed citations
16.
Tahir, Stephen K., Xiufen Yang, Mark G. Anderson, et al.. (2007). Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737. Cancer Research. 67(3). 1176–1183. 250 indexed citations
17.
Morgan-Lappe, Susan E., Lora A. Tucker, Xiaoli Huang, et al.. (2007). Identification of Ras-Related Nuclear Protein, Targeting Protein for Xenopus Kinesin-like Protein 2, and Stearoyl-CoA Desaturase 1 as Promising Cancer Targets from an RNAi-Based Screen. Cancer Research. 67(9). 4390–4398. 114 indexed citations
18.
Sarthy, Aparna V., Susan E. Morgan-Lappe, Dorothy Zakula, et al.. (2007). Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Molecular Cancer Therapeutics. 6(1). 269–276. 66 indexed citations
19.
Lin, Xiaoyu, Susan E. Morgan-Lappe, Dorothy Zakula, et al.. (2006). ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene. 26(27). 3972–3979. 200 indexed citations
20.
Morgan-Lappe, Susan E., Keith W. Woods, Mark E. Schurdak, et al.. (2005). RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene. 25(9). 1340–1348. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ángel Santiago Breakdown of academic impact, for papers by Steven A. Enkemann Breakdown of academic impact, for papers by Linda Kessler Breakdown of academic impact, for papers by David Batt Breakdown of academic impact, for papers by Gaynor Davies Breakdown of academic impact, for papers by Maria F. Camargo Breakdown of academic impact, for papers by Hui Qu Breakdown of academic impact, for papers by Alejandro Parrales Breakdown of academic impact, for papers by Akriti Kharbanda Breakdown of academic impact, for papers by Lena Kanter
Rankless by CCL
2026